Clinical and biochemical effects during
treatment of depression with
nortriptyline: The role of
1 0 - hydroxynortriptyline
Plasma concentrations of nortriptyline (NT) and its major metabolite 10-hydroxy-NT (10-0H-NT) were
measured in 30 patients with depression, treated with NT for 3 weeks. Nine patients who recovered
completely had plasma concentrations of NT and 10-0H-NT ranging from 358 to 728 nmol/L and from
428 to 688 nmol/L, respectively. Of the 21 patients who did not recover completely, only four had plasma
concentrations within the window limited by these two plasma concentration ranges. A correlation was
found between the degree of amelioration and the plasma concentration of NT (r, = 0.469; P < 0.01).
Lumbar punctures were performed in 26 patients before and after 3 weeks of NT treatment. Dur-
ing treatment there was a 30.9% mean decrease in the noradrenaline metabolite 4-hydroxy-3-me-
thoxyphenylglycol (HIVIPG) in cerebrospinal fluid (CSF). We could not evaluate the extent to which this
decrease was caused by NT or 10-0H-NT, respectively, because both are strong inhibitors of noradrenaline
uptake. The ratio between the concentration of NT and 10-0H-NT in CSF correlated to the reduction
of HA/PG in CSF (r = 0.397; P < 0.05) and to the amelioration of depression (r, = 0.623; P < 0.001).
This might indicate that NT and 10-0H-NT interact on the noradrenaline system in a nonadditive way.
During treatment there was a 15.2% decrease in CSF concentration of the serotonin metabolite
5-hydroxyindoleacetic acid. The reduction was significantly correlated to the CSF concentration of NT
but not to that of 10-0H-NT. This is in accordance with the fact that NT is a more potent inhibitor of
serotonin uptake than is 10-0H-NT. The dopamine metabolite homovanillic acid in CSF decreased
significantly by 10.0%. The biochemical data indicate that noradrenergic, serotoninergic, and dopamin-
ergic systems are affected by NT treatment and that 10-0H-NT might be more selective on noradrenergic
neurons than the parent drug. (CLIN PHARMACOL THER 1987;42:10-9.)
Conny Nordin, M.D., Leif Bertilsson, Ph.D., and Bo Siwers, M.D. Huddinge, Sweden
Interpretation of the plasma concentration-effect re-
lationship of a drug is complicated by the occurrence
of active metabolites.' The major metabolite of nor-
triptyline (NT), 10-hydroxy-NT (10-OH-NT) inhibits
From the Departments of Psychiatry and Clinical Pharmacology at
the Karolinska Institute, Huddinge University Hospital.
Supported by grants from the Swedish Medical Research Council
(Nos. 3902 and 5454), the Karolinska Institute, and the Soder-
Received for publication Sept. 19, 1986; accepted Dec. 26, 1986.
Reprint requests: Dr. C. Nordin, Department of Psychiatry, Huddinge
Hospital, S-141 86 Huddinge, Sweden.
noradrenaline (NA) uptake with a potency about 50%
that of NT.2 Because 10-0H-NT concentrations in
plasma and cerebrospinal fluid (CSF) usually are higher
than those of the parent drug,' 10-0H-NT probably
contributes to the effects of NT on the noradrenergic
system and may thereby influence NT's antidepressant
Treatment of depression with an NA uptake in-
hibitor like NT decreases the CSF concentration of
the NA metabolite 4-hydroxy-3-methoxyphenyl glycol
(HMPG), probably as a result of feedback inhibition of
transmitter biosynthesis .4 Analogously, treatment with
inhibitors of serotonin uptake such as chlorimipramine
Table I. Data on patients
and zimeldine results in a decreased level of the sero-
tonin metabolite 5-hydroxyindoleacetic acid (5-HIAA)
in CSF.' NT also slightly decreases 5-HIAA in CSF,
suggesting that it inhibits serotonin uptake.' A recent
study' shows that treatment with NT inhibits serotonin
uptake by platelets and that this effect is much stronger
for NT than for 10-0H-NT.
It has been hypothesized that CSF concentrations of
5-HIAA7" of the dopamine metabolite homovanillic
acid (HVA)12'13 and of HMPG-14 may predict the outcome
of treatment with various antidepressant drugs. Thus
endogenously depressed patients with high CSF con-
centrations of 5-HIAA (>15 ng/ml) have been reported
to respond better to NT than do patients with a lower
(<15 ng/ml) concentration.' However, relationships are
difficult to evaluate because of the many factors influ-
encing CSF concentrations of transmitter metabolites. '5
We have now examined indirectly the clinical and
biochemical roles of 10-0H-NT during treatment of
depression with NT.
The study included 39 nondelusional, depressed in-
patients who came to our psychiatric clinic on their own
initiative and who fulfilled the Feighner criteria for pri-
mary depression.' The subjects had a median depres-
sion score of 17, which reflects a depression of mod-
erate severity (see Methods) (Table I). All were judged
by two experienced psychiatrists to require inpatient
care. All were physically healthy according to history,
routine laboratory tests, and physical examination.
None of the patients had received treatment with an-
tidepressants or neuroleptics for 1 month before inclu-
sion. Some patients had been given occasional doses
of benzodiazepines during this period.
During an initial placebo period five patients were
excluded because of spontaneous recovery. Four pa-
tients left the study during the first week of NT treat-
ment. Of these, two recovered, one discontinued med-
ication because of a severe orthostatic reaction, and one
was excluded after a reconsideration of the Feighner
criteria. Data on the subjects are given in Table I. Of
the 30 patients with depression who completed 3 weeks
of treatment, 27 had unipolar disorder, two had bipolar
disorder with histories of manic episodes, and one had
bipolar disorder with previous hypomanic episodes.
After a placebo period of 3 to 7 days, NT (Sensaval,
Pharmacia Laboratories) treatment was begun at 50 mg
t.i.d. (8 AM, 2 PM, and 10 Pm) in 31 patients, 50 mg
b.i.d. (8 AM and 10 Pm) and 25 + 50 mg (8 AM and
10 Pm) in two patients with histories of side effects,
and 25 mg b.i.d. (8 AM and 10 Pm) in a 75-year-old
patient. These doses were maintained for at least 3
weeks except for the four patients excluded who were
treated with 50 mg t.i.d. Occasional daily doses of
nitrazepam (5 mg) or oxazepam (15 to 30 mg) were
Plasma samples were drawn at 8 AM, before the
morning dose of NT, once or twice a week from the
second week of treatment. Blood was collected in hep-
arinized glass tubes and centrifuged within 30 minutes.
Plasma was separated and stored at
ysis. All samples from each patient were analyzed si-
multaneously by mass fragmentography.19-" The re-
ported values of NT and unconjugated 10-0H-NT (sum
of E and Z isomers) are the means of the concentrations
measured during the second and the third weeks of
Lumbar punctures were performed by a standardized
technique at the level L 4-L 5 before and after 3 weeks
of NT treatment. Twelve milliliters of CSF was col-
lected in the early morning with the patient in a sitting
position after at least 8 hours of fasting and strict bed
rest. CSF samples were centrifuged immediately,
frozen in 3 ml aliquots in silanized glass tubes, and
stored at 20° C until analysis. CSF samples from
each patient were analyzed simultaneously. Concentra-
tions of NT, unconjugated 10-OH-NT (sum of E and Z
20° C until anal-
(mean ± SD)
46 ± 8
43 ± 13
45 ± 8
44 ± 13
45 ± 8
44 ±- 12
After the placebo period
After 3 weeks of NT treatment
Depression and 10-hydroxynortriptyline
EF. Self-inhibiting action of nortriptyline's antidepres-
sive effect at high plasma levels. A randomized, double-
blind study controlled by plasma concentrations in pa-
tients with endogenous depression. Psychopharmacology
Montgomery S, Braithwaite R, Dawling S, McAuley R.
High plasma nortriptyline levels in the treatment of
depression. I. CLIN PHARMACOL THER 1978;23:309-14.
Ziegler VE, Clayton PJ, Taylor JR, Co BT, Biggs JT.
Nortriptyline plasma levels and therapeutic response.
CLIN PHARMACOL THER 1976;20:458-63.
Haefely W, Hfirlimann A, Thoenen E. Scheinbar para-
doxe Beeinflussung von peripherer Noradrenalinwirkun-
gen durch einige Thymoleptika. Hely Psycho! Acta
Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nor-
din C. Extremely rapid hydroxylation of debrisoquine: a
case report with implication for treatment with nortrip-
tyline and other tricyclic antidepressants. Ther Drug
van Praag HM, Korf J. Endogenous depressions with and
without disturbances in the 5-hydroxytryptamine metab-
olism: a biochemical classification? Psychopharmacology
Asberg M, Thoren P, Traskman L, Bertilsson L, Ring-
berger V. "Serotonin depression"a biochemical sub-
group within the affective disorders? Science 1976;
Depression and 10-hydroxynortriptyline 19
van Praag HM. Significance of biochemical parameters
in the diagnosis, treatment and prevention of depressive
disorders. Biol Psychiatry 1977;12:101-34.
Gibbons RD. Consistent evidence for a biological subtype
of depression characterized by low CSF monoamine
levels. Acta Psychiatr Scand 1986;74:8-12.
Carlsson A, Corrodi H, Fuxe K. Hokfelt T. Effects of
some antidepressant drugs on the depletion of intraneu-
ronal brain catecholamine stores caused by 4,a-dimethyl-
metatyramine. Eur J Pharmacol 1969;5:367-73.
Kopin IJ, Blomberg P. Ebert MH, et al. Disposition and
metabolism of MHPG-CD, in humans: plasma MHPG
as the peripheral pathway of norepinephrine metabolism
and as an important determinant of CSF levels of MHPG.
In: Usdin E, Asberg M, Bertilsson L, Sjoqvist F, eds.
Frontiers in biochemical and pharmacological research
in depression. New York: Raven Press, 1984:57-68.
Moir ATB, Ashcroft GW, Crawford TBB, Eccleston D,
Guldberg HC. Cerebral metabolites in cerebrospinal fluid
as a biochemical approach to the brain. Brain 1970;
Nordin C, Bertilsson L, Siwers B. Site of lumbar punc-
ture influences levels of monoamine metabolites. Arch
Gen Psychiatry 1982;39:1445.
Thor& P, Asberg M, Bertilsson L, Mellstrom B, Sjoq-
vist F, Traskman L. Clomipramine treatment of obses-
sive-compulsive disorder. Arch Gen Psychiatry 1980;37: